SCHEMBL6779576

SCHEMBL6779576

N=C(N)Nc1cc(C(=O)NCC(=O)O)cc(C(F)(F)F)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RHOC P08134 5/20 0.48
RHOA P61586 5/20 0.48
HTT P42858 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
P2RX1 P51575 2/20 0.45
LMNA P02545 1/20 0.45
TACR1 P25103 1/20 0.43
GPR35 Q9HC97 1/20 0.42
GAA P10253 1/20 0.42
NNMT P40261 1/20 0.41
ALDH1A1 P00352 1/20 0.40
EGLN1 Q9GZT9 1/20 0.40
TRPA1 O75762 1/20 0.40
CYP1A2 P05177 1/20 0.40
ATF1 P18846 1/20 0.40
NFKB1 P19838 1/20 0.40
BCHE P06276 1/20 0.39
HDAC3 O15379 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6775633 0.99 RHOC (0.47) RHOCRHOAHTTL3MBTL1P2RX1
SCHEMBL6778978 0.82 ITGB3 (0.55) RHOCRHOAHTTL3MBTL1LMNA
SCHEMBL6376058 0.82 P2RY14 (0.50) P2RX1LMNATACR1GPR35GAA
SCHEMBL615919 0.82 TACR1 (0.59) RHOCRHOAHTTL3MBTL1P2RX1
SCHEMBL7347520 0.80 RHOC (0.43) RHOCRHOAHTTL3MBTL1P2RX1
SCHEMBL6773907 0.79 ITGB3 (0.53) RHOCRHOA
SCHEMBL6777228 0.79 ITGB3 (0.53) RHOCRHOA
SCHEMBL3898783 0.78 KDM4E (0.53) RHOCRHOAHTTL3MBTL1TACR1
SCHEMBL7373492 0.78 RHOC (0.41) RHOCRHOAHTTL3MBTL1P2RX1
SCHEMBL27401708 0.77 P2RX1 (0.43) RHOCRHOAP2RX1GPR35GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6831199-B1 In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 G. D. SEARLE & CO. 2004-12-14 US disclosed
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP disclosed
US-6028223-A AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS G. D. SEARLE & CO. (US) 2000-02-22 US disclosed
EP-0850221-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1998-07-01 EP disclosed
WO-1997008145-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1997-03-06 WO disclosed